Puma Biotech breast cancer drug likely approved in Europe after reexamination
A committee of the European Medicines Agency is likely to approve the drug, five months after regulators recommended against approval
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | European Medicines Agency (EMA)